Document is current

Article History

Received: 23 March 2023

Accepted: 31 July 2023

First Online: 14 September 2023

Declarations

:

: This study was approved by the ethics committee of the medical faculty of Heinrich Heine University Düsseldorf (Reg. 2016034986). All patients signed a written consent for participation. We confirm that we have read the Journal’s position on issues involved in ethical publication and affirm that this work is consistent with those guidelines.

: The authors have the right to publish the data expressed in the manuscript.

: LW has previously received funding grants and institutional support from the German Research Foundation, Hilde-Ulrichs-Stiftung für Parkinsonforschung, and the ParkinsonFonds Germany, BMBF/ERA-NETNEURON, DFG Forschergruppe (FOR1328), Deutsche Parkinson Vereinigung (DPV), Forschungskommission, Medizinische Fakultät, HHU Düsseldorf, UCB; Medtronic, UCB, Teva, Allergan, Merz, Abbvie, Roche, Bial, Merck, Novartis, Desitin, Spectrum. Author Lars Wojtecki owned stock in company BioNTech SE. Lars Wojtecki is consultant to the following companies: TEVA, UCB Schwarz, Desitin, Medtronic, Abbott/Abbvie, MEDA, Boehringer I, Storz Medical, Kyowa Kirin, Guidepoint, Merck, Merz, Synergia, BIAL, Zambon, Sapio Life, STADA, Inomed. Vertanical.AKF received honoraria from Springer Medizin Verlag GmbH, Heidelberg, Germany; Springer-Verlag GmbH, Berlin; ProLog Wissen GmbH, Cologne, Germany; Bundesverband Klinische Linguistik e.V., Coburg, Germany; Hochschule Fresenius, Düsseldorf, Germany; as well as Seminar- und Fortbildungszentrum Rheine, Germany; and has received grants from the German Parkinson Society; German Alzheimer’s Society; Federal Joint Committee (G-BA); and STADAPHARM GmbH.EK has received honoraria from ProLog Wissen GmbH, Cologne, Germany; Kyowa Kirin Services LTD, London, United Kingdom; AbbVie Inc., as well as from the Movement Disorders Society; and has received grants from German Ministry of Education and Research (BMBF); German Parkinson Society; German Alzheimer’s Society; Federal Joint Committee (G-BA); and STADAPHARM GmbH.The other authors have no competing interests to declare.